Experts call for ‘urgent reform’ of side-effect reporting on cancer tr
- This topic has 0 replies, 1 voice, and was last updated 12 years, 3 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Experts call for ‘urgent reform’ of side-effect reporting on cancer trials.
“Dr Witteles and co-author Dr Melinda Telli first became concerned after encountering a number of patients suffering from heart problems following treatment with the cancer drug sunitinib.
The drug has been approved by the US FDA, and is also approved for use on the NHS under its trade name, Sutent, for the treatment of kidney and gastrointestinal cancers, and pancreatic neuroendocrine tumours.”
Viewing 1 post (of 1 total)
- The forum ‘Websites’ is closed to new topics and replies.